BioScience Health Innovations, Inc. Annual Report: A Plain-English Guide

I’m breaking down how BioScience Health Innovations performed this year. My goal is to cut through the corporate jargon so you can decide if this company fits your portfolio.

1. What does this company do?

BioScience Health Innovations operates through its subsidiary, Best 365 Labs, Inc.

They focus on "mitochondrial health"—how your cells create energy. They sell supplements and peptides directly to consumers, anchored by their "MODS Max" delivery system. This technology uses lipid-based capsules to protect nutrients from stomach acid, which the company reports helps the body absorb 40% more nutrients than standard pills.

2. Financial performance: A major turnaround

The company is no longer just a startup with no sales. They had a strong 2025:

• Revenue: They brought in $5.69 million in 2025. That is a 208% jump from the $1.84 million they made in 2024, driven by a 150% increase in customers.
• Profit: They are officially profitable, clearing $642,090 in profit for 2025, up from $87,000 the year before.
• Efficiency: Their profit margin grew from 4.7% to 11.3%, reflecting improved manufacturing efficiency and lower customer acquisition costs.

3. What changed this year?

The company spent the second half of 2025 upgrading its infrastructure to support growth. They migrated to a new e-commerce platform capable of handling over 50,000 visitors a month and implemented Oracle NetSuite software to automate inventory and accounting. They funded these $350,000 upgrades using their own cash flow, signaling a shift toward more professionalized business operations.

4. Key risks: The "Penny Stock" trap

Despite the growth, this remains a high-risk investment:

• "Penny Stock" Rules: Because the stock trades at $4.00 and is not on a major exchange, it is classified as a "penny stock." Brokers must follow strict rules before you can trade it, which can make it difficult to buy or sell quickly and often results in a large gap between the price you want and the price you get.
• Low Trading Volume: There are only 53 shareholders. On many days, fewer than 500 shares trade. Because so few shares are available, even a small trade can cause the price to swing wildly, and you may find it difficult to exit your position when you want to.
• Control Issues: The Board of Directors has the authority to issue new shares with special voting rights without shareholder approval. This could reduce your ownership percentage or limit your influence on company decisions.
• Regulatory Pressure: The company must keep its financial filings up to date to maintain its listing. If they miss a deadline, brokers may be restricted from showing the stock price, effectively freezing your investment.

My Take

BioScience has transformed from a shell into a business with growing profits, which is a significant achievement. However, the stock remains difficult to trade. You are betting on a growing company, but you are also betting on your ability to find a buyer when you are ready to sell. Given the thin trading volume and regulatory hurdles, treat this as a speculative move. Only invest if you are comfortable with the possibility that your capital could be tied up for a long time.

Before you buy: Check your broker’s specific policies on "penny stocks" or "OTC" (Over-the-Counter) securities. Some platforms have extra fees or restrictions for these types of trades, so it is worth a quick call to your brokerage to see how they handle this specific ticker.